CD62P、CD40L及节律核受体Rev-erbα在缺血性脑卒中不同发病时间的表达

doi:10.3969/j.issn.1006-7795.2025.01.006

首都医科大学学报 ›› 2025, Vol. 46 ›› Issue (1): 34-40.doi: 10.3969/j.issn.1006-7795.2025.01.006

• 国家卫生健康委加强脑卒中防治工作减少百万新发残疾工程 • 上一篇下一篇

CD62P、CD40L及节律核受体Rev-erbα在缺血性脑卒中不同发病时间的表达

王银平¹, 孟灿灿², 吴文娟², 杨直堂^2*

1.河北工程大学临床医学院临床医学专业，河北邯郸 056000；2.河北工程大学附属医院神经内科，河北邯郸 056000

收稿日期:2024-09-03 出版日期:2025-02-21 发布日期:2025-02-24
通讯作者: 杨直堂 E-mail:hszfym@sina.com
基金资助:
国家自然科学基金项目（82271507），河北省卫健委项目（20240968），邯郸市科学技术研究与发展计划项目（19422083011-5），河北省政府资助优秀人才项目。

The expressions of CD62P, CD40L, and Rev-erbα after ischemic stroke on different onset times

Wang Yinping¹, Meng Cancan², Wu Wenjuan², Yang Zhitang^2*

1.Clinical Medical College of Hebei Engineering University, Handan 056000, Hebei Province, China; 2. Department of Neurology, Affiliated Hospital of Hebei Engineering University, Handan 056000, Hebei Province, China

Received:2024-09-03 Online:2025-02-21 Published:2025-02-24
Supported by:
This study was supported by National Natural Science Foundation of China (82271507) ,Health Commission of Hebei Province Program (20240968), Science and Technology Research and Development Program of HanDan City(19422083011-5), Provincial Medical Excellent Talent Project of Hebei Provincial Government.

摘要/Abstract

摘要： 目的研究缺血性脑卒中患者不同发病时间的节律核受体Rev-erbα及血小板活化因子P-选择素（CD62P）、肿瘤坏死因子CD40L表达水平，为缺血性脑卒中提供新的治疗方法。方法将158例因缺血性脑卒中住院的患者作为缺血性脑卒中组，根据发病时间分为4个亚组：T₁(0~6点)组32人、T₂(6~12点)组50人、T₃(12~18点)组40人、T₄(18~24点)组36人。将同时间非缺血性脑卒中住院的126例患者作为对照组，分别为T₁组32人，T₂组31人，T₃组32人，T₄组31人。患者入院后采集血浆和血小板标本，通过酶联免疫吸附试验(enzyme linked immunosorbent assay,ELISA)检测CD62P、CD40L及Rev-erbα表达水平。结果缺血性脑卒中组T₂时间段CD62P、CD40L及Rev-erbα的表达明显高于其他时间段(P＜0.05)，且CD62P及CD40L表达水平变化与Rev-erbα的表达变化相一致，而T₁、T₃、T₄三组之间的CD62P、CD40L与Rev-erbα的表达差异无统计学意义（P>0.05）。缺血性脑卒中组各时间段CD62P、CD40L和Rev-erbα表达均明显高于对照组(P＜0.05)，结论节律核受体Rev-erbα及血小板活化水平在缺血性脑卒中后表达明显增高，特别是在凌晨时间段，并且血小板活化水平与节律核受体Rev-erbα表达在时间上是一致的，提示Rev-erbα与血小板活化在缺血性脑卒中发病中发挥了重要作用，并且它们之间存在明显的关联。

关键词: 缺血性脑卒中, 血小板活化, CD62P, CD40L, 节律核受体Rev-erbα

Abstract: Objective To investigate the expression levels of platelet activating factor and rhythm nuclear receptor Rev-erbα in patients after ischemic stroke on different onset times. Methods A total of 158 patients after ischemic stroke admitted from June 2022 to May 2023 were divided into four groups according to the onset time T₁ (0-6 o'clock), T₂ (6-12 o'clock), T₃ (12-18 o'clock), and T₄ (18-24 o'clock). Matched to the ischemic stroke groups, 126 patients hospitalized at the same time with non-ischemic stroke were divided into four groups. General data and serum samples of the subjects were collected, and the expression levels of CD62P, CD40L and Rev-erbα were detected with enzyme-linked immunosorbent assay (ELISA). Results The expressions of platelet activating factor CD62P, tumor necrosis factor CD40L, and rhythm nuclear receptor Rev-erbα in T₂ group after ischemic stroke were significantly higher than that in the other groups (P< 0.05), whilst no significant difference were observed in other three groups （P>0.05). The expression of CD62P, CD40L and rev-erbα in ischemic stroke groups were significantly higher than that in control groups. Conclusion The expression levels of the rhythm nuclear receptor Rev-erbα, CD62P, and CD40L in ischemic stroke groups is higher than that in control groups, and the expression of these cytokines is more significant in T₂ group (i.e. early in the morning) than other time slot. On the other hand, the expressions of CD62P and CD40L are consistent with Rev-erbα on the time slots, indicating a clear correlation. It is indicated Rev-erbα and platelet activation play a key role on attacking of ischemic stroke.

Key words: ischemic stroke, platelet activation, CD62P, , CD40L, rhythm nuclear receptor Rev-erbα

中图分类号:

R743.3

王银平, 孟灿灿, 吴文娟, 杨直堂. CD62P、CD40L及节律核受体Rev-erbα在缺血性脑卒中不同发病时间的表达[J]. 首都医科大学学报, 2025, 46(1): 34-40.

Wang Yinping, Meng Cancan, Wu Wenjuan, Yang Zhitang. The expressions of CD62P, CD40L, and Rev-erbα after ischemic stroke on different onset times[J]. Journal of Capital Medical University, 2025, 46(1): 34-40.

参考文献

［1］ Feigin V L, Brainin M, Norrving B, et al. World Stroke Organization (WSO): global stroke fact sheet 2022［J］. Int J Stroke, 2022, 17(1): 18－29.
［2］ Feigin V L, Stark B A, Johnson C O, et al. Global, regional, and national burden of stroke and its risk factors, 1990－2019: a systematic analysis for the Global Burden of Disease Study 2019［J］. Lancet Neurol, 2021, 20(10): 795－820.
［3］杨璞. 最新版《中国脑卒中防治指导规范》发布［N］. 家庭医生报, 2021-11-29 (01).
［4］ Khaku A S, Tadi P. Cerebrovascular disease［M］. Treasure Island: StatPearls, 2023.
［5］ Singh B, Huang D Y. The role of circadian rhythms in stroke: a narrative review［J］. Neurochem Res, 2024, 49(2): 290－305.
［6］ Walker W H 2nd, Walton J C, DeVries A C, et al. Circadian rhythm disruption and mental health［J］. Transl Psychiatry, 2020, 10(1): 28.
［7］ Adlanmerini M, Lazar M A. The REV-ERB nuclear receptors: timekeepers for the core clock period and metabolism［J］. Endocrinology, 2023, 164(6): bqad069.
［8］ Ryu W S, Hong K S, Jeong S W, et al. Association of ischemic stroke onset time with presenting severity, acute progression, and long-term outcome: a cohort study［J］. PLoS Med, 2022, 19(2): e1003910.
［9］ van der Meijden P E J, Heemskerk J W M. Platelet biology and functions: new concepts and clinical perspectives［J］. Nat Rev Cardiol, 2019, 16(3): 166－179.
［10］ Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis［J］. Blood, 2010, 116(20): 4317－4327.
［11］ Yun S H, Sim E H, Goh R Y, et al. Platelet activation: the mechanisms and potential biomarkers［J］. Biomed Res Int, 2016, 2016: 9060143.
［12］中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018［J］ . 中华神经科杂志, 2018, 51(9): 666-682.
［13］ Kamat P K, Khan M B, Smith C, et al. The time dimension to stroke: circadian effects on stroke outcomes and mechanisms［J］. Neurochem Int, 2023, 162: 105457.
［14］ Lo E H, Albers G W, Dichgans M, et al. Circadian biology and stroke［J］. Stroke, 2021, 52(6): 2180－2190.
［15］ Shi J, Tong R,Zhou M, et al. Circadian nuclear receptor Rev-erbα is expressed by platelets and potentiates platelet activation and thrombus formation［J］. Eur Heart J, 2022, 43: 2317－2334.
［16］ Schuhmann M K, Stoll G, Bieber M, et al. CD84 links T cell and platelet activity in cerebral thrombo-inflammation in acute stroke［J］. Circ Res, 2020, 127(8): 1023－1035.
［17］ Rawish E, Nording H, Münte T, et al. Platelets as mediators of neuroinflammation and thrombosis［J］. Front Immunol, 2020, 11: 548631.
［18］ Buurma M, Van Diemen J J K, Thijs A, et al. Circadian rhythm of cardiovascular disease: the potential of chronotherapy with Aspirin［J］. Front Cardiovasc Med, 2019, 6: 84.
［19］ Feuring M, Wehling M, Ruf A, et al. Circadian variation of platelet function measured with the PFA－100［J］. Platelets, 2009, 20(7): 466－470.
［20］ Mayeuf-Louchart A, Zecchin M, Staels B, et al. Circadian control of metabolism and pathological consequences of clock perturbations［J］. Biochimie, 2017, 143: 42－50.
［21］ Duez H, Staels B. The nuclear receptors Rev-Erbs and RORs integrate circadian rhythms and metabolism［J］. Diab Vasc Dis Res, 2008, 5: 82－88.
［22］ Everett J L, Lazar M A. Nuclear receptor Rev-erbα: up,down,and all around［J］. Trends Endocrinol Metab, 2014, 25: 586－592.

[1]	詹艳丽, 李一吟, 李平, 孙景萍, 黄良通, 蔡学礼. 基于区域卒中分级诊疗网络救治急性缺血性脑卒中的现状及疗效分析[J]. 首都医科大学学报, 2025, 46(1): 41-47.
[2]	张萌, 马咏馨, 贾琼, 张东威, 张昕红, 徐耀铭. 静脉溶栓治疗急性轻型非致残性缺血性脑卒中有效性和安全性的临床观察：一项单中心回顾性观察研究[J]. 首都医科大学学报, 2025, 46(1): 56-62.
[3]	乔玥, 李传辉, 赵文博. 急性缺血性脑卒中的再灌注治疗的现状与未来[J]. 首都医科大学学报, 2025, 46(1): 68-70.
[4]	李兴茂, 李秀, 王婷, 赵鑫, 王德杨, 商海燕, 赵咏梅, 李森. GLP-1 受体激动剂对 2 型糖尿病患者急性缺血性脑卒中后认知功能的影响[J]. 首都医科大学学报, 2024, 45(6): 1029-1037.
[5]	顾超雄, 李明. 不忘初心，砥砺前行，做科研先锋——中国工程院院士吉训明教授[J]. 首都医科大学学报, 2024, 45(3): 375-378.

CD62P、CD40L及节律核受体Rev-erbα在缺血性脑卒中不同发病时间的表达

The expressions of CD62P, CD40L, and Rev-erbα after ischemic stroke on different onset times

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价